DrugDashboards

Brimonidine Tartrate/Timolol Maleate Ophthalmic Solution

Brimonidine Tartrate and Timolol Maleate · BRIMONIDINE TARTRATE 2 mg/mL; TIMOLOL MALEATE 5 mg/mL · Solution · Ophthalmic · Caplin Steriles Limited

NDC 65145-0164-01 · 1 BOTTLE, DROPPER in 1 CARTON / 15 mL in 1 BOTTLE, DROPPER · ANDA · View full market →

The short version

4 companies supply this market — a reasonable cushion if one runs into trouble. The price has fallen 73% in a year, to $1.84 per mL — and generics that get this cheap tend to get abandoned rather than defended. Put together: this looks like a healthy supply — the boring kind, which is exactly what you want.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

$0$2.50$5.00$7.50Oct 2025Sep 2026$1.84
12 price points · per MLSource: CMS NADAC

Estimated fill cost

WAC per package, as filed
$175.00
Reported to Texas DSHS · 2026 annual filing · Caplin Steriles USA Inc

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Supply fragility

13Low risk

Some pressure is visible, but not much — here’s everything the score found to count.

  • 4 active manufacturers+5
  • Class I/II recall on same molecule/form in past 12 months+8

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.1%chance of a new FDA shortage posting for brimonidine tartrate and timolol maleate (other) in the next 90 days

OAI inspection at a producing facility (24 months) · sole-source market · 2 Class I/II recall(s) in 12 months

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Regulatory

Application
ANDA219093
TE code
AB
Approval date
Feb 25, 2025
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Brimonidine Tartrate and Timolol Maleate (Solution)

LabelerStrengthFirst seenLast seen
Caplin Steriles LimitedBRIMONIDINE TARTRATE 2 mg/mL; TIMOLOL MALEATE 5 mg/mLJul 15, 2026Sep 3, 2026
Apotex Corp.BRIMONIDINE TARTRATE 2 mg/mL; TIMOLOL MALEATE 5 mg/mLJul 15, 2026Sep 2, 2026
Florida Pharmaceutical Products, LLCBRIMONIDINE TARTRATE 2 mg/mL; TIMOLOL MALEATE 5 mg/mLJul 15, 2026Sep 2, 2026
Leading Pharma, LLCBRIMONIDINE TARTRATE 2 mg/mL; TIMOLOL MALEATE 5 mg/mLJul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Brimonidine Tartrate/Timolol Maleate Ophthalmic Solution — NDC 65145-0164-01," retrieved September 3, 2026, https://drugdashboards.com/drug/65145016401.

Free to cite with attribution — see how the data is put together.